A Double-blind Trial of Synthetic Salmon Calcitonin in the Treatment of Acute Pancreatitis

Publisher Website
Google Scholar
Abstract
A multicenter randomized double-blind trial on the use of synthetic salmon calcitonin (SCT) was carried out in 94 patients with acute pancreatitis. In addition to strict standard treatment—without aprotinin, atropine, or antacids—50 patients received daily 3 × 20 μg = 300 MRCU SCT intravenously and 44 patients received placebo for 6 days. Mortality rate was not influenced, overall mortality being 5.3%. The number of patients without pain and with normalized serum amylase on a given day was significantly higher in the group treated with SCT. Other parameters such as doses of analgesics, leukocyte count, and normalization of seven defined clinical and laboratory criteria within 6 days showed a positive trend without reaching significance.